Literature DB >> 15699685

The effect of zinc salts on serum bilirubin levels in hyperbilirubinemic rats.

Libor Vítek1, Lucie Muchová, Jaroslav Zelenka, Marie Zadinová, Jirí Malina.   

Abstract

OBJECTIVES: Intestinal metabolism of bilirubin is implicated in the pathogenesis of neonatal jaundice and Crigler-Najjar syndrome. In the present study the authors investigated the effect of oral administration of zinc salts on serum bilirubin levels in hyperbilirubinemic rats.
METHODS: Bilirubin-binding activities of zinc sulfate and water-insoluble zinc methacrylate were determined in vitro. Congenitally hyperbilirubinemic Gunn rats and artificially hyperbilirubinemic Wistar rats were used in in vivo studies. Animals were fed a normal diet for 1 week and then a treatment diet of either zinc sulfate or zinc methacrylate for additional 2 weeks. Serum and fecal bile pigments were determined at the end of each phase. Biliary bilirubin secretion rates were determined in hyperbilirubinemic Wistar rats fed zinc methacrylate.
RESULTS: Substantial bilirubin-binding activities of zinc salts were demonstrated in in vitro experiments. Treatment with oral zinc salts significantly decreased serum bilirubin levels in Gunn rats (166 +/- 53 versus 123 +/- 38 and 206 +/- 34 versus 131 +/- 31 micromol/L, P < 0.05 for zinc methacrylate and zinc sulfate, respectively). A similar effect of zinc methacrylate was also observed in hyperbilirubinemic Wistar rats (102 +/- 10 versus 14 +/- 4 micromol/L, P < 0.0001). In accord, biliary bilirubin secretion decreased significantly in these animals (45 +/- 11 versus 28 +/- 4 nmol/h 100g body weight, P < 0.02). In contrast to zinc sulfate, treatment with zinc methacrylate did not lead to the elevation of serum zinc levels.
CONCLUSIONS: Oral administration of zinc salts efficiently decreased serum bilirubin levels in hyperbilirubinemic rats, presumably as a result of inhibition of enterohepatic circulation of bilirubin. This approach might be useful in the treatment of severe unconjugated hyperbilirubinemias.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699685     DOI: 10.1097/00005176-200502000-00010

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

Review 1.  Oral zinc for the prevention of hyperbilirubinaemia in neonates.

Authors:  Satish Mishra; Aminderjit Cheema; Ramesh Agarwal; Ashok Deorari; Vinod Paul
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

2.  Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration.

Authors:  A C Bulmer; J S Coombes; J T Blanchfield; I Toth; R G Fassett; S M Taylor
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

3.  Efficacy of zinc in reducing hyperbilirubinemia among at-risk neonates: a randomized, double-blind, placebo-controlled trial.

Authors:  Nidhi Rana; Satish Mishra; Shinjini Bhatnagar; Vinod Paul; Ashok Kumar Deorari; Ramesh Agarwal
Journal:  Indian J Pediatr       Date:  2011-04-01       Impact factor: 1.967

4.  Earlier Nutrient Fortification of Breastmilk Fed LBW Infants Improves Jaundice Related Outcomes.

Authors:  Xiao Wei Ma; Wei Qi Fan
Journal:  Nutrients       Date:  2020-07-17       Impact factor: 5.717

5.  Comparison of hyperbilirubinemia incidence between the newborns of zinc-taking and non-zinc-taking mothers during the third trimester of pregnancy.

Authors:  Hassan Boskabadi; Gholamali Maamouri; Maryam Zakerihamidi; Atiyeh Mohammadzadeh Vatanchi; Mohammad Sokhtanloo; Marzieh Sadat Mousavi; Sara Ghahremani; Fatemeh Bagheri
Journal:  Caspian J Intern Med       Date:  2021

6.  Evaluation of Serum Zinc Levels in Hyperbilirubinemic Neonates Before and After Phototherapy.

Authors:  Ziba Mosayebi; Maral Rahmani; Shahin Behjati Ardakani; Mahdi Sheikh; Mamak Shariat; Golnaz Rezaeizadeh
Journal:  Iran J Pediatr       Date:  2016-03-17       Impact factor: 0.364

7.  Efficacy of zinc sulfate on indirect hyperbilirubinemia in premature infants admitted to neonatal intensive care unit: a double-blind, randomized clinical trial.

Authors:  Gholamreza Faal; Hoda Khatib Masjedi; Gholamreza Sharifzadeh; Zahra Kiani
Journal:  BMC Pediatr       Date:  2020-03-19       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.